Press releases

2016-03-22 – Press release

Topas Therapeutics Raises EUR 14 Million to Treat Immunological Disorders

Causal therapies based on novel approach for antigen-specific tolerance induction
Significant opportunities through near term clinical proof-of-concept (“POC”)
Strong strategic syndicate includes Epidarex Capital, EMBL Ventures, Gimv, and Evotec AG